Going gets tough for Elder Pharma COO

According to the CBI the firm owes over Rs 150 crore to fixed deposit investors and over Rs 1500 crore to lenders and creditors

Going gets tough for Elder Pharma COO
Aneesh Phadnis Mumbai
Last Updated : Oct 18 2016 | 1:22 PM IST

Don't want to miss the best from Business Standard?


Trouble is mounting for Anuj Saxena, chief operating officer of Elder Pharmaceuticals as the Central Bureau of Investigation has secured a non bailable warrant against him in a bribery case.

Saxena is accused of paying bribes to former director general of corporate affairs ministry B K Bansal to hush up an investigation against the firm.

Anuj is the younger son of Jagdish Saxena, the late founder of Elder Pharmaceuticals. He has acted in television serials including a popular soap Kkusum.

But events in the recent months have not gone according to his script.

In July the CBI arrested Bansal for accepting Rs 9 lakh in bribe for not ordering a Serious Fraud Investigation Office probe against Elder Pharma.

Bansal and his 30 year old son Yogesh committed suicide in September accusing CBI of harassment. Two months earlier, his wife and daughter ended their lives citing the same reason.

The Mumbai based firm was already in thick of controversy facing multiple complaints of defaults of fixed deposit payments and winding up petitions.

According to the CBI the firm owes over Rs 150 crore to fixed deposit investors and over Rs 1500 crore to lenders and creditors.

Elder Pharma's last communication to the stock exchange was in February to inform the appointment of new independent directors. In July the exchange sought a response on media reports of default but there was none. Last October, it informed the exchange it was trying to raise funds and exploring sale of its subsidiaries in Britain and Bulgaria. The firm had then said litigations were being filed against it to malign its image.

In 2014, the company sold two of its divisions comprising 30 brands to Torrent Pharma for Rs 2,004 crore.

Experts cannot understand why despite this huge cash flow and its substantial assets, the company has not been able to meet its small commitments. Business Standard reported in  April some write-offs and other entries in the company's books were also  questioned by its auditors.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Oct 18 2016 | 12:50 PM IST

Next Story